Longitudinal study of 18 children with perinatal LAV/HTLV III infection: attempt at prognostic evaluation.
We performed a longitudinal study (mean follow-up 19.5 months, range 3 to 42 months) in 18 consecutive children with clinical symptoms of LAV/HTLV III infection. Twelve patients were born to mothers infected with LAV/HTLV III, and six were infected by blood products administered during the first weeks of life. Immunologic studies included lymphocyte markers, in vitro responses to mitogens and antigens with corresponding skin tests, and antibody response with isoagglutinins, post-vaccination antibodies, and Candida. A serologic profile of antibody to GP110, P18, and P25 LAV/HTLV III antigens by radioimmunoprecipitation assay was also performed. The antigen-induced proliferative responses were normal in 10 patients who had a stable course, but were profoundly impaired in eight others who died or had poor condition with opportunistic infections. These in vitro measurements were well correlated with antigen skin tests. An abnormal antibody response to antigens, a low level of isoagglutinins, and a peculiar profile of LAV/HTLV III antibodies were also frequently observed in these eight patients. These measurements appear to be of prognostic value because they were noticed soon after onset of clinical symptoms.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000276:immunology* / Q000401:mortality / Q000635:transmission; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D002675:Child, Preschool; D000090266:Chromobox Protein Homolog 5; D005183:Failure to Thrive / Q000209:etiology; D006801:Humans; D007111:Immunity, Cellular; D007223:Infant; D008137:Longitudinal Studies; D008213:Lymphocyte Activation; D009894:Opportunistic Infections / Q000209:etiology; D011379:Prognosis; D014611:Vaccination
D000914:Antibodies, Viral; C000715594:CBX5 protein, human; D000090266:Chromobox Protein Homolog 5